Levine Cancer Institute
Before starting at the Levine Cancer Institute, Shebli Atrash, M.D., worked on multiple myeloma in Little Rock, Arkansas. In 2011, he served as an Assistant Professor of Medicine at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences in Little Rock, AR. Post-graduation he studied cancer cell biology. His work mostly focused on proteomics analysis of proteasome inhibitors’ effects on myeloma cell lines.
Currently, he serves as a member of the Plasma Cell Disorders program at the Levine Cancer Institute. Their team focuses on clinical trials and translational science for multiple myeloma. Dr. Atrash concentrates primarily on immunotherapies and investigator-initiated clinical trials for high-risk multiple myeloma.